Reciprocally, the CCL2-STAT3 axis also is activated directly in PCa cells downstream of AR signaling and combination therapy targeting the AR and the CCL2/CCR2/STAT3 pathway effectively prevents EMT in PCa cells in vitro and suppresses xenograft growth in vivo [73,122]. The gene discussed is CCL2; the disease is posterior cortical atrophy.